🇺🇸 FDA
Patent

US 10407484

Compositions and methods for modulating T-cell mediated immune response

granted A61KA61K39/3955A61K45/06

Quick answer

US patent 10407484 (Compositions and methods for modulating T-cell mediated immune response) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K39/3955, A61K45/06, A61K47/68, A61K47/6937